IRVINE, Calif. — October 10, 2022 — Immunis, Inc., a private biotech company developing a novel treatment for age and disease-related immune decline, announces that its Chairman Hans Keirstead, Ph.D. will present the keynote address at the Aging and Gerontology Conference in Dubai. The Aging and Gerontology Conference is a renowned international event that brings together longevity entrepreneurs, pharma and biotech companies, investors, researchers, and government organizations with the goal of extending human health span.

During their lifetime, all humans experience a reduction in healthy immune cell numbers and their secreted factors (secretome), which are necessary to promote immune system development and to circumvent age and disease-related immune decline. Immunis recently developed a novel method of directing clinically compliant human stem cells to a young precursor population that produces a non-cellular secretome product (STEM) which benefits immune system modulation and health. Dr. Keirstead’s keynote will detail Immunis’ administration of STEM in an FDA-approved Phase 1/2a human clinical trial to test STEM’s efficacy in elderly patients with age-related and disease-enhanced muscle atrophy.

About Aging and Gerontology Conference

The Aging and Gerontology conference is focused on cellular & molecular repair of age-associated disease. The conference strives to help medical professionals in the geriatric field and the public to understand, empathize and take action to aid the individuals worldwide. For additional information about the Aging and Gerontology Conference please visit: www.agingcongress.com

About Immunis Inc.

Immunis is a private biotechnology company developing a novel immunomodulatory secretome product for the various manifestations of age and disease-related immune decline. The STEM product line leverages Immunis’ leading-edge capabilities in stem cell technologies to deliver a product of all natural, all human immune modulators in their natural relative physiological concentrations. For additional information about Immunis’ IMM01-STEM Phase 1/2a trial please visit: www.immunisbiomedical.com

About STEM-MYO

Immunis’ FDA-awarded Phase 1/2a clinical trial is an open-label dose escalation study to assess the safety and tolerability of IMM01-STEM in elderly participants with muscle atrophy associated with knee osteoarthritis. Up to 18 patients will be enrolled in the trial and randomly assigned to an IMM01-STEM dose cohort. Treatment will be administered in the form of intramuscular injections twice a week for four weeks (8 injections total). Male or female patients are eligible for the study if they satisfy the following criteria: (1) 50 to 75 years of age at the time of signing the informed consent, (2) have a grade 2 or 3 knee osteoarthritis as defined by Kellgren-Lawrence analyses, (3) have quadricep weakness (<7.5N/kg), (4) can ambulate >50 feet unassisted, (5) are negative for human immunodeficiency virus, hepatitis B surface antigen (HBsAg), and hepatitis C at the Screening Visit and (6) have a body mass index (BMI) of <40kg/m². For additional information about Immunis’ trial participant qualifications, please visit:  www.immunisbiomedical.com

Cautionary Note Regarding Forward-Looking Statements

This communication contains statements that constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as applicable. Forward-looking statements include, but are not limited to, statements regarding our plans, beliefs, expectations and assumptions, as well as other statements that are not necessarily historical facts. You are cautioned that these forward-looking statements are only predictions and involve risks and uncertainties. Further, any forward-looking statement speaks only as of the date as of which it is made, and we do not intend to update or revise any forward-looking statements. This communication also contains market data related to our business and industry which includes projections that are based on several assumptions we believe are reasonable and most significant to the projections as of the date of this communication. If any of our assumptions prove to be incorrect, our actual results may significantly differ from our projections based on these assumptions. This communication is neither an offer to sell nor a solicitation of an offer to buy any of the securities described herein.